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ABSTRACT
Nanotechnology is gaining more and more consensus in sev-
eral application fields, comprised in-body applications. In-
novative therapies and diagnostic approaches are based on
the use of injections or oral delivery of nanoparticles. The
acceleration of this type of development makes very urgent a
deeply and accurate analysis of the interaction between the
nanoparticles and the biological fluid where the nanoparti-
cles are immersed.
In this paper, we focus on Titanium (T i and its alloy (e.g., T iO2)
systems, given their specific features in terms of density, lack
of cytotoxic effects, etc.. Specifically, we design and study
an in-body system by characterizing the emission and diffu-
sion processes. Further, we propose an experimental study
of the morphology and other important characteristics (e.g.
the pH of the particles, and the dielectric constant of the
solution) of nano-T iO2 systems when immersed in a Ringer
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solution, in order to derive important information related to
their potential toxicity inside the human body.
Categories and Subject Descriptors
I.6 [Simulation and Modeling]: Miscellaneous; I.6.5 [Model
Development]: Modeling methodologies—complexity mea-
sures, performance measures
General Terms
Theory, Experimentation
Keywords
In-body area nanonetwork, titanium nanoparticles, Ringer
solution, nanoparticle emission and diffusion
1. INTRODUCTION
Nanotechnology is a new research field that finds applica-
tions in several areas. In nanomedicine, the use of nanode-
vices (i.e. nanorobots and nanosensors, opportunely func-
tionalized or inner drugged with medicament) may not only
improve the therapeutic index of drugs by improving their
effectiveness, and increasing their tolerability in the body
by interfering at a minimum level with the immune sys-
tem [1], but also for diagnostic purposes [2, 3, 4] even if the
related security and privacy issues present very important
challenges [5].
Different types of nanoparticles can be exploited for na-
nomedicine applications, and are constructed from a huge
range of organic and inorganic materials, such as emulsions,
Solid Lipid Nanoparticles (SLNs), gold nanoparticles, sil-
ver nanoparticles, titanium dioxide T i02 nanoparticles, den-
drimers, Carbon Nano-Tubes (CNTs), etc. just to mention
the main types [6]. All these materials can be used as car-
riers for localized Drug Delivery Systems (DDSs) and for
diagnostic scopes when opportunistically functionalized. In
the first case, the aim is to provide a locally controlled drug
concentration, where the medication is needed [2]. The sec-
ond case is to provide information about in-body conditions,
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by opportunistically measuring specific parameters and/or
chemical concentrations, etc. [3].
Noble metals, like silver and gold, are largely used for the
design of nanoparticles in the field of sensing applications,
as well as acting as carriers of medicament molecules. Par-
ticularly, colloidal silver has been used as an antibacterial
agent by weakening DNA replication and inactivating pro-
teins, while gold has low toxicity to biological systems, and
so results inefficient for antibiotic therapy [7].
In addition, nanoparticles are also engineered to provide sus-
tained drug release [8, 9], especially beneficial for chronic
therapies. In [10], the authors use gold nanoparticles for
diagnostic and drug delivery applications by exploiting chi-
tosan, with the dual purpose of (i) acting as a reducing
agent in the synthesis of gold nanoparticles, and also (ii)
promoting the penetration and uptaking the peptide hor-
mone insulin across the mucosa.
For both DDS and diagnostic applications, common meth-
ods adopted include (a) inhalation, (b) intravenous and in-
tramuscular injection and (c) ingestion/oral [11]. In all these
methods, the most important thing is to characterize the
interaction between the in-body solution and the specific
nanoparticles.
The contribution of this paper is twofold: (i) the charac-
terization of the T i02 nanoparticles emission, and diffusion
processes, and (ii) an experimental analysis of the T i02
nanoparticles in a biologic-like fluidic medium, in order to
infer main features as pH, diffraction patterns and dielectric
constant.
Notice that the choice of T i02 nanoparticles is due to their
benefits for biomedical applications. Indeed, among other
existing systems, because of their low density, excellent cor-
rosion resistance, lack of cytotoxic effects, good mechanical
properties, T i and its alloys, T i02 are well established ma-
terials for biomedical application as orthopedic and dental
implants, cardiovascular stents, joint replacement [12], [13,
14, 15, 16]. Addition of a controlled drug delivery charac-
teristic to T iO2 nanoparticles could enlarge its potential use
in biomedical fields.
This paper is organized as follows. In Section 2 we present
our general (and not specific to materials discussed later in
the paper) nanoparticulate model suitable both for injec-
tion of tablets and liquids containing nanoparticle concen-
tration. We highlight the main processes that occur when
a concentration of nanoparticles (i.e. T i02 nanoparticles
in our case) is introduced in what we name here “compart-
ment” to indicate a closed volume containing a biological
fluid. Specifically, we detail the laws characterizing the emis-
sion/ transmission 1 and diffusion processes. In Section 3 we
describe the details of the experiment we dealt in order to
infer the main characteristics of the interactions between the
nanoparticles and the biological fluid. Finally, conclusions
are drawn at the end of the paper.
1In this paper, the terms emission and transmission are in-
terchanged.
2. CHARACTERIZATION OF THE IN-BODY
PHASES
In this section, we describe the two main processes that char-
acterize the pharmacokinetics model we considered in this
work, namely the emission and the diffusion.
2.1 Nanoparticle emission process
In our model, we rely on the pharmacokinetics laws, which
provide a mathematical basis for analyzing how the human
body reacts to the administration of “external substances”
(i.e. a fluid with a given nanoparticle concentration). Phar-
macokinetics considers the rate at which drug concentrations
change in the body, and includes the kinetics of absorption,
distribution, metabolism and excretion of a drug.
There exist three approaches of pharmacokinetics modeling
i.e., (i) compartmental, (ii) physiological, and (iii) model-
independent. The first is an empirical approach, where the
compartment can represent a body/organ volume. Usually
one or two compartments are used. The physiological model
identifies the compartments with actual body spaces. The
model is more complex than the compartmental models; it is
largely used for predictions, and is more suitable for clinical
therapy, and when changing situations like alterations of
flow rates due to conditions such as swelling, or fever occur.
Finally, the model-independent approach is the most recent,
but does not provide any specific information about how the
drug is distributed.
In this paper, we rely on one compartment model for oral
drug administration, so that we can model a compartment
with a biological fluid (e.g. the Ringer solution as described
in Section 3) into which a flow of nanoparticles is added by
a rapid single dose. Notice that the multi-particulate DDSs
show reproducible pharmacokinetics behavior than conven-
tional (monolithic) formulations; this means that after dis-
integration, which occurs within a few minutes (often even
within seconds), the individual nanoparticles are released
within the “compartment”.
After such a period (i.e., t1 [s]), we assume that the nanopar-
ticle concentration i.e., CNP (t1), is uniform in the “com-
partment”, and has reached a maximum value. The analysis
of this model relies on a simple mass balance compliant with
the dissolution kinetics of T i02 nanoparticles [17] that have
been used in the experiments described in Section 3.
The mass balance model that provides the nanoparticle trans-
mission rate in the compartment model is expressed as
rTx(t) =
dCNP (t)
dt
= kdcin − keCNP (t) , (1)
where CNP (t) is the nanoparticle concentration behavior
along time, cin is the initial nanoparticle concentration, kd
[min−1] and ke [h
−1] are the first-order dissolution and elim-
ination rate constants, respectively. The solution of (1) is
obtained by integration:
CNP (t) =
kd
kd − ke
· C0 [exp (−ket)− exp (−kdt)] , (2)
where C0 [L
−1] represents the amount of nanoparticles (dose)
at zero concentration. The peak of nanoparticle concentra-
tion in the compartment corresponds to CNP (t = t1), i.e.,
CNP (t1) =
NNP
V
, (3)
with NNP as the quantity of nanoparticles in the volume V .
Notice that V has no direct physiological meaning, but cor-
responds to the apparent volume of distribution, defined as
that volume of plasma in which the total amount of nanopar-
ticles in the compartment would be required to be dissolved
in order to reflect the nanoparticles concentration attained
in plasma.
Fig. 1 depicts the behavior of nanoparticles in the compart-
ment i.e., the nanoparticle concentration versus time. We
assumed C0 = 100 [L
−1], ke = 0.0578 [h
−1], and differ-
ent values of dissolution constant i.e., kd = (0.03, 0.05, 0.07)
[min−1]. The value of kd = 0.03 corresponds to the disso-
lution kinetics constant of the T i02 nanoparticles [18]. We
notice that the concentration increases faster for higher val-
ues of dissolution constant, while it decreases very slowly
due to typical value of elimination constant, that is
ke =
ln(2)
t1/2
, (4)
where t1/2 [h] is the elimination half-life, that is the time
required for the concentration of the nanoparticles to reach
half of its original value (i.e., t1/2 = 12 h).
Notice that the behavior of nanoparticle concentration in
the compartment reflects that of a pulse-based modulation
scheme [19], where a transmitter nanomachine instantaneously
releases a pulse of molecules. Indeed, due to the nano-scale
size of nanoparticles approximable to that of molecules, we
can consider the nanoparticle concentration behavior as a
spike, followed by a slow decrease of concentration, as de-
picted in Fig. 1.
The time instant when the nanoparticle concentration reaches
the peak is t1 [min], and the analytical expression can be ob-
tained by derivation of (2), posed equal to zero, such as
dCNP (t)
dt
=
kdC0
kd − ke
· d [exp (−ket)− exp (−kdt)]
dt
= 0, (5)
from which follows that
t1 =
1
(kd − ke)
· ln
(
kd
ke
)
, (6)
where kd 6= ke. This expression represents the time instant
for which the concentration of emitted nanoparticles reaches
its global maximum, and can be interpreted as the nanopar-
ticle concentration delay [min], depending on the values of
dissolution and elimination constants. Notice that this de-
lay represents the time for the whole dose of nanoparticles
to be emitted outside the tablet; for higher values of the
dissolution constant kd, the delay decreases, meaning that
the nanoparticle concentration reaches the peak faster.
Fig. 2 depicts the nanoparticle transmission delay, versus
the dissolution constant. It is intuitive that higher the dis-
solution rate (i.e., kd), lower will be the transmission delay
occurring from the emission process at the transmitter (i.e.,
the tablet) up to the diffusion process, where the maximum
nanoparticle concentration has been delivered.
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Figure 1: Nanoparticle concentration within the
compartment model, for different values of the dis-
solution constant. Higher the dissolution constant,
faster the increase of concentration.
Another feature is the nanoparticle concentration width tw [min]
that represents the time interval from t1 up to t2, where t2
is that value corresponding to an amplitude of NP concen-
tration greater than half of its maximum value, that is:
CNP (t2) =
CNP (t1)
2
, (7)
which becomes
NNP
2V
=
kd
kd − ke
C0 [exp (−ket2)− exp (−kdt2)] , (8)
and simplified provides the value of t2 [min], that is
t2 = −
1
ke − kd
ln
(
NNP
2V
· kd − ke
kdC0
)
. (9)
From (9), we can obtain the expression of the nanoparticle
concentration width tw [min] as
tw = t2 − t1, (10)
where by substituting (6) and (9), we obtain:
tw = −
1
ke − kd
ln
(
NNP
2V
· kd − ke
kdC0
)
− 1
kd − ke
ln
(
kd
ke
)
,
(11)
which becomes
tw =
1
(kd − ke)
· ln NNP
C0V
. (12)
2.2 Nanoparticle diffusion process
The diffusion process can be studied by distinguishing two
cases i.e., (i) the ideal, and (ii) non-ideal case. In the
first scenario, the nanoparticle concentration is assumed as
homogeneous and no nanoparticle is lost during the diffu-
sion. On the other hand, in the non-ideal case a portion of
nanoparticles is lost and cannot reach a destination point.
In an ideal case, the concentration is assumed homogeneous
and the residence time attains a mean reference value. Un-
fortunately, in a real reactor the nanoparticle fluid spends a
different time inside the reactor, depending on specific char-
acteristics of the compartment. The ideal case that models
the compartment can be represented through a bioreactor.
A bioreactor is a reactor that utilizes either a living organism
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Figure 2: Transmission delay of nanoparticle con-
centration within the compartment model, versus
different values of the dissolution constant. Higher
the dissolution constant, lower the nanoparticle
transmission delay.
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Figure 3: Binding concentration within the com-
partment model, which occurs for t > 5 s, and in-
creases until reaching the maximum value NB.
or one or more enzymes from a living organism to accomplish
a certain chemical transformation.
For the non-ideal case, from (1), the nanoparticle transmis-
sion rate rT (t) can be identified with the nanoparticle con-
centration flux JT (x, t) at the output of the tablet i.e., for
x = xT . The particle concentration flux JT (x, t) is depen-
dent on the nanoparticle concentration gradient at time t
and position x through the Fick’s first law, as follows
JT (x, t) = −D∇CNP (x, t) , (13)
where D [cm2/s] is the diffusion coefficient, assumed as a
constant value for a given fluidic medium, and depending
on the size and shape of nanoparticles, as well as the inter-
action with the solvent and viscosity of the solvent. Unfor-
tunately, the Fick’s first law works when applied to steady
state systems, namely the concentration will keep constant
both along the space and in the time. In our application,
the concentration changes during the time, since nanopar-
ticles diffuse along the space by determining different levels
of concentrations. For that, we need to consider the Fick’s
second law. In practice, the diffusion associated with the
degradation kinetics yields to the following mass balance:
δCNP (x, t)
δt
= D
δ2CNP (x, t)
δx2
+ b′ · CNP (x, t) , (14)
where b′ is a kinetic rate constant, and CNP is the drug
concentration as transmitted from the previous phase. Due
to the thinness of the wall as compared to the overall ”com-
partment” radius, we can use Cartesian coordinates as ap-
proximation instead of cylindrical coordinates.
We consider our compartment with a total volume V , and a
flux going through the two reactors (i.e., F ). Then, we can
apply and solve the mass balances that follow directly from
(14). The concentration of magnitude CNP corresponds to
the nanoparticle dose in the tablet. The mass balance on
the first reactor can be modeled as a first order differential
equation, that is
dC1(t)
dt
= −
(
2F
V
+ k
)
C1(t) +
(
2F
V
+ k
)
Cinput(t), (15)
with the following conditions
C1(t = 0) = 0, Cinput(t) = CNP · δ(t). (16)
This leads to the solution for C1(t) as
C1(t) = CNP · exp [−(k + 1/τ)t], (17)
where τ = V
2F
. The quantity (CNP − C1(t)) corresponds
to the portion of nanoparticle concentration that will be di-
rectly eliminated by the body, without reaching the receiver.
As an analogy to (15), we can write the following mass bal-
ance equation:
dC2(t)
dt
= −
(
2F
V
+ k
)
C2(t)+
(
2F
V
+ k
)
·exp [−(k + 1/τ)t],
(18)
whose solution is
C2(t) =
CNP · t
τ
· exp [−(k + 1/τ)t], (19)
which represents the concentration of dissolved nanoparticles
in the compartment.
As we modelled a scenario as a fluidic medium where nanopar-
ticles are free to move following the diffusion laws until
reaching the target cells 2, they are able to form chemi-
cal bindings with them. Thus, from (19), we can obtain the
concentration of bindings i.e., Cb (t), formed due to the dis-
solved nanoparticles bound with the receptors, which can be
described by the following formula:
Cb (t) · u (t− δ) =
{
NB ·
[
1− exp
(
− t−δ
τ
)]
, t > δ
0, t ≤ δ
(20)
where NB is the maximum number of bindings that can
occur i.e., NB = maxC2 (t), τ [s] is the delay necessary
for the binding formation, δ [s] is the start time of the re-
ception process that is related to the diffusion delay of the
nanoparticles, and u(t) is the Heaviside step function. Fig-
ure 3 shows the trend of binding concentration, obtained
under the assumption that NB = 100, δ = 5 s, and τ = 3 s.
2As an instance, a target cell is a tumor cell that has been
previously detected.
3. IN-BODY MODELING: EXPERIMENTAL
EVALUATION AND CHARACTERIZATION
In this section we will describe the details and features of the
nanoparticles, and the solution considered to infer the main
features of the interaction between nanoparticles and body-
like fluid solution. Specifically, we will study the morphology
of the nanoparticles and any pH variations, as well as the
dielectric constant of the considered solutions.
Nano−T iO2 (anatase, nanopowder, 99.99% purity; Sigma-
Aldrich) and an aqueous solution of chlorides of sodium,
potassium and calcium in the same concentrations as nor-
mal body fluids (Ringer solution, 7.5 ml lactic acid, 5.85 g
NaCl, 300 ml H2O di grade 2 purity, and 700 ml H2O and
regulation of the pH to 6.9− 7.0) were used for the experi-
ments. This solution is often used as a physiological solution
for in vitro study of biomaterials due to its similarity to the
body environment.
Two different T iO2 particle sizes have been selected for the
experiments, with the aim to assess how this parameter can
guide the interactions between the biological system and spe-
cific therapeutic nanostructure. Static immersion test has
been performed at 37◦C (± 0.4◦ C) by adding the nanopar-
ticles by a rapid single dose. The study has been carried out
monitoring the following parameters:
1. the structure and the morphology of the nanoparticles
before and after their permanence in the physiological
solution for 14 days by SEM (Scanning Electron Mi-
croscope) observation and X-ray diffraction analysis;
2. the pH of the solution containing the nanoparticles
at a prefixed time and comparing them to the pH
of the physiological solution maintained in the same
condition without any nanoparticles inside. Moreover,
experimental determination of the complex dielectric
constant of the physiological solutions with different
concentrations of nanoparticles (i.e. loadings), com-
paring the results to the un-loaded physiological solu-
tion.
The size of the particles has been measured by Small-angle
X-Ray scattering technique, as depicted in Figure 4. Accord-
ing to this study the most frequent radius of the particles
is (i) 40.0A◦ (Sample type 1) with a surface-to-volume ra-
tio 3 equal to 0.1003(A◦)−1, and (ii) 44.0A◦ (Sample type
2) with a surface-to-volume ratio equal to 0.1422(A◦)−1. A
non-homogeneous particles size has a positive effect during
the reactions that occur at the surface of the nanoparticles
during the bonding of the drugs and consequently during
their distribution and transport.
The particle shape and their surface reactivity can influence
the transport properties of other particles in the body en-
vironment, and thus affecting the adhesion kinetics of the
3Also called surface-area-to-volume ratio, and represents the
amount of surface area per unit volume of an object or col-
lection of objects. It is frequently used to characterize ma-
terials with very small diameter (powder), or very porous or
that are otherwise not compact.
(a)
(b)
Figure 4: Size distribution by volume of (a) 40µm,
and (b) 44µm TiO2 nanoparticles.
therapeutic particles loaded on and their transfer to the fa-
vorite position. Figure 5 (a) and (c) confirm the previously
obtained results, that is, the T iO2 nanoparticles used for this
study are not perfectly homogeneous as their size concerns,
and additionally, because their non-spherical shape can be
beneficial to improve drug transport and delivery efficiency
as compared to the identical spherical particles.
In such conditions, the difference in curvature between nanopar-
ticles favours an increased loading efficiency and leads ob-
taining higher attachment to the specific therapeutic par-
ticles and a vascular barrier. The nanoparticles show a
slightly different microstructure following their permanence
in the physiological solution. Indeed, the agglomeration of
the nanoparticles takes place (Figure 5 (b) and (d), and the
enhancement of their surface area occurs.
The surface area-to-volume ratio influences the reactions,
which occur at the surface; it derives that the particles with
a higher surface area have a higher number of reaction sites
compared to the particles with a lower surface area, thus
resulting in enhanced chemical reactivity. In addition, both
T iO2 surfaces show a high tendency to be wetted by the
aqueous solution, due to a strong affinity for water.
Apart from the presence of tetragonal Titanium Oxide in
both X-ray diffraction spectra, the presence of monoclinic
Titanium Hydrogen Oxide has been detected, as shown in
Figure 5: SEM microstructure of the T iO2 nanopar-
ticles at the beginning of the analysis for (a) 40µm,
and (c) 44µm size, and following the extraction from
the physiological solution after 14 days, for (b) 40µm,
and (d) 44µm size.
Figure 6, following their permanence in the physiological
solution. The chemical bond established between the T iO2
nanoparticles and O, and H atoms coming from the aque-
ous solution, is an un-stable configuration and confers a hy-
drophilic character to the nanoparticles, independently form
their size, which results to be more reactive towards any
chemical compounds.
Finally, by checking the pH of the solutions for 14 days, no
any modification of this parameter was obtained i.e., the pH
value of the simulated body environment remains the same
during the experiment (pH= 6.9−7.0). This corresponds to
the absence of any release of T i ions in the physiological so-
lution and indicates a non-toxic character of the considered
system.
Experimental characterization of the complex dielectric con-
stant of solutions with different T iO2 concentrations [20, 21]
has been carried out using 85070D Dielectric Probe Kit (Ag-
ilent, now Keysight Technology) attached to a E8361A PNA
Network Analyzer (10 MHz to 67 GHz), and compared with
the Ringer solution and distilled water reference cases.
A fstep = 10 MHz frequency step between fmin = 60 MHz
and fmax = 8 GHz has been considered. Real and imagi-
nary parts are reported in Figure 7 and 8 in the considered
frequency band. The values are shown splitting the over-
all considered frequency band in the interval [60, 200] MHz,
and from 100 MHz to 8 GHz. For the sake of completeness
the measured values of the distilled water (also used for the
calibration) are also reported.
The dispersion in the considered wide frequency band is ba-
sically determined by the Ringer solution’s characteristics.
A high value of losses in the low frequency range can be ob-
served, that has a minimum around the f ≈ 2÷3 GHz range.
Above this frequency the imaginary part of εeff asymptot-
Figure 6: X-Ray diffraction patterns for the starting
T iO2 and following the extraction from the physio-
logical solution after 14 days
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Figure 7: Variation of the real (left) and imaginary
(right) part of the complex dielectric constant in the
range [60, 200] MHz for different solutions.
ically approaches the reference (i.e., distilled water curve).
The real part of the doped liquid has a more significative
variation with respect to the imaginary part that is not in-
fluenced by the presence of the T iO2 nanoparticles. On the
other hand, the real part feels both the concentrations and
dimensions of the nanoparticles. This observation allows en-
visaging changes of the concentration and/or dimensions of
the T iO2 nanoparticles based on other considerations de-
pending on the thought-out applications, as for example
quantity of the drug to be delivered, characteristics of the
targeted organs, etc.
4. CONCLUSIONS AND FUTURE DIREC-
TIONS
In this paper, we investigated how nanoparticles are injected
in the human body for nanomedicine applications. The be-
havior at the nano-scale is described by means the modeling
of the emission, and diffusion processes. Specifically, the
one compartment model for oral drug administration is pre-
sented and discussed. T iO2 nanoparticles and a biological
fluid system as possible carriers to sustain drugs have been
studied.
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Figure 8: Variation of the real (left) and imaginary
(right) part of the complex dielectric constant in the
range from 100 MHz to 8 GHz for different solutions.
This research shows the possibility of combining the biocom-
patibility of T iO2 to the drug delivery features and their use
in biomedical field. We observed the complete absence of
any release of T i ions in the physiological solution demon-
strating, once again, a non-toxic character of the considered
system. The particles with a high surface area show a higher
tendency to be wetted by the aqueous biological solution and
they can support more efficiently any drug loaded on their
surfaces.
As future work, we will consider the morphological differ-
ences in such a way to match them with specific and differ-
ent tasks, e.g. based on their properties they can be more
suitable for drug delivery or for diagnostic purposes. For
the last aspects is of paramount importance to take into ac-
count all the specific features and then the specific require-
ments needed. Furthermore, we are planning to investigate
deeply the interactions between the signalling features with
the specific system introduced in this work, namely the “in-
vivo-like” environment with nano-T iO2 particles immersed
in the Ringer solution.
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